Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer

Drugs R D. 2005;6(5):299-305. doi: 10.2165/00126839-200506050-00006.

Authors

Alberto Montero¹, Daniel Booser, Laura Esparza-Guerra, James Murray, Marguerite Rosales, Gabriel Hortobagyi, Vicente Valero

Affiliation

¹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230-1439, USA.

PMID: 16128600
DOI: 10.2165/00126839-200506050-00006

No abstract available

Publication types

Clinical Trial, Phase I
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Docetaxel
Dose-Response Relationship, Drug
Doxorubicin / administration & dosage
Doxorubicin / adverse effects
Doxorubicin / therapeutic use
Drug Administration Schedule
Female
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
Humans
Middle Aged
Neoplasm Metastasis
Recombinant Proteins
Taxoids / administration & dosage
Taxoids / adverse effects
Taxoids / therapeutic use
Treatment Outcome

Substances

Recombinant Proteins
Taxoids
Docetaxel
sargramostim
Doxorubicin
Granulocyte-Macrophage Colony-Stimulating Factor